Johnson & Johnson (NYSE:JNJ) Shares Purchased by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 1.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,087 shares of the company’s stock after buying an additional 374 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,628,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Accurate Wealth Management LLC lifted its holdings in Johnson & Johnson by 8.4% in the 4th quarter. Accurate Wealth Management LLC now owns 23,214 shares of the company’s stock worth $3,298,000 after buying an additional 1,806 shares in the last quarter. Wynn Capital LLC increased its position in shares of Johnson & Johnson by 1.4% in the 4th quarter. Wynn Capital LLC now owns 12,647 shares of the company’s stock worth $1,829,000 after purchasing an additional 178 shares during the last quarter. Fiduciary Financial Group LLC increased its position in shares of Johnson & Johnson by 5.8% in the 4th quarter. Fiduciary Financial Group LLC now owns 4,370 shares of the company’s stock worth $621,000 after purchasing an additional 240 shares during the last quarter. Pacifica Partners Inc. increased its position in shares of Johnson & Johnson by 17.1% in the 4th quarter. Pacifica Partners Inc. now owns 35,046 shares of the company’s stock worth $5,047,000 after purchasing an additional 5,111 shares during the last quarter. Finally, Quad Cities Investment Group LLC increased its position in shares of Johnson & Johnson by 6.4% in the 4th quarter. Quad Cities Investment Group LLC now owns 2,950 shares of the company’s stock worth $427,000 after purchasing an additional 178 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $144.74 on Thursday. The company has a 50-day moving average of $149.12 and a 200-day moving average of $156.09. The company has a market capitalization of $348.48 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $2.66 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JNJ. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Guggenheim boosted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.